How a leading European pharma company enabled its embrace of digital health
Boehringer Ingelheim (BI) wanted to enable its distinct therapeutic areas, as well as its upstream R&D functions to embrace digital solutions. It needed to ensure that the company did this in ways that focused on solving clear problems, rather than pushing technology into situations where it didn’t fit demand.
Designed a program to embrace remote monitoring, patient engagement, physician education, and upstream R&D requirements through an internal group of experts. This group was the company’s key interface to the start-up community, and later spun out a Corporate Venture Capital arm focused on healthtech
Teamed with BI’s Therapeutic Areas to design digital health interventions tailored to market needs, adapting these for circumstances across major national markets
Collaborated tightly with the client to develop requirements for specific apps and other programs, then screened start-ups and other firms for potential partnership and development deals
BI created many external partnerships with healthtech companies to bring digital solutions to patients and physicians, and it built internal stakeholders’ comfort and capability with embracing these new types of solutions to achieve key business aims.